Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation

Cancer Letters

Volumn 329, Issue 2, 2013, Pages 189-196

  Chen, Minghui ^a   Yu, Le ^a   Gu, Chunping ^a   Zhong, Desheng ^a   Wu, Shuguang ^a   Liu, Shuwen ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Celecoxib; Cisplatin; COX 2; Gastric cancer

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CARRIER PROTEIN; CELECOXIB; CISPLATIN; COPPER TRANSPORTER 1; CYCLOOXYGENASE 2; INDOMETACIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIMESULIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DNA ADDUCT; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TRANSPORT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DNA ADDUCTS; DRUG INTERACTIONS; FEMALE; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR FLUID; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRAZOLES; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872496832     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.030     Document Type: Article

References (26)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Meyer H.J., Wike H. Treatment strategies in gastric cancer. Dtsch. Arztebl. Int. 2011, 108:698-706.
3. Pasini F., Fraccon A.P., Manzoni G.DE. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011, 31:3543-3554.
4. Kim S.H., Kim S.H., Song Y.C., Song Y.S. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase. Ann. NY Acad. Sci. 2009, 1171:635-641.
5. Li W.Z., Wang X.Y., Li Z.G., Zhang J.H., Ding Y.Q. Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. J. Oral. Pathol. Med. 2010, 39:579-584.
6. Mizutani Y., Nakanishi H., Li Y.N., Sato N., Kawauchi A., Miki T. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J. Urol. 2004, 172:1474-1479.
7. Sugiura T., Saikawa Y., Kubota T., Suganuma K., Otani Y., Watanabe M., Kumai K., Kitajima M. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In vivo 2003, 17:229-233.
8. Thiel A., Mrena J., Ristimaki A. Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev. 2011, 30:387-395.
9. Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S., Nakatani K., Nakano H., Sugimura T., Terada M. P53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res. 1991, 51:5800-5805.
10. Yu L., Wu W.K., Li Z.J., Liu Q.C., Li H.T., Wu Y.C., Cho C.H. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol. Pharmacol. 2009, 75:1364-1373.
11. Holzer A.K., Samimi G., Katano K., Naerdemann W., Lin X., Safaei R., Howell S.B. The copper influx transporter human copper transporter protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004, 66:817-823.
12. Samimi G., Safaei R., Katano K., Holzer A.K., Rochidi M., Tomioka M., Goodman M., Howell S.B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10:4661-4669.
13. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
14. Blair B.G., Larson C.A., Safaei R., Howell S.B. Copper tranporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin. Cancer Res. 2009, 15:4312-4321.
15. Larson C.A., Blair B.G., Safaei R., Howell S.B. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol. Pharmcol. 2009, 75:324-330.
16. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48:495-535.
17. Howell S.B., Safaei R., Larson C.A., Sailor M.J. Copper transporter and the cellular pharmacology of the platinum-containing cancer drugs. Mol. Pharmacol. 2010, 77:887-894.
18. Holzer A.K., Katano K., Klomp L.W., Howell S.B. Cispaltin rapidly downregulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 2004, 10:6744-6749.
19. Holzer A.K., Howell S.B. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res. 2006, 66:10944-10952.
20. Ford A.C. Chemoprevention for gastric cancer. Best Pract. Res. Clin. Gastroenterol. 2011, 25:581-592.
21. Wu W.K., Sung J.J., Lee C.W., Yu J., Cho C.H. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010, 295:7-16.
22. Chan M.W., Wong C.Y., Cheng A.S., Chan V.Y., Chan K.K., To K.F., Chan F.K., Sung J.J., Leung W.K. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. Oncol. Rep. 2007, 18:1557-1562.
23. Yu L., Chen M., Li Z., Wen J., Fu J., Guo D., Jiang Y., Wu S., Cho C.H., Liu S. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol. Pharmacol. 2011, 79:608-617.
24. Safaei R., Holzer A.K., Katano K., Samimi G., Howell S.B. The role of copper transporters in the development of resistance to Pt drugs. J. Inorg. Biochem. 2004, 98:1607-1613.
25. Hu P.J., Yu J., Zeng Z.R., Leung W.K., Lin H.L., Tang B.D., Bai A.H., Sung J.J. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004, 53:195-200.
26. Oshima H., Popivanova B.K., Oguma K., Kong D., Ishikawa T.O., Oshima M. Activation of epidermal growth factor receptor signaling by the prostaglanin E(2) receptor EP4 pathway during gastric tumorigenesis. Cancer Sci. 2011, 102:713-719.